Peptide therapeutics is currently offering a new commercial potential to pharmaceuticals and biotechnology industry. To exploit this emerging market, large pharmaceutical and biotechnological firms are actively investing in development of newer peptides for various applications and are also opting for newer technologies for syntheses of these peptides. Cancer is the leading cause of death globally; according to the WHO (World Health Organization), around 12.7 million new cancer cases occurred in the year 2008. About 7 million people die from cancer every year and it is estimated that there will be more than 16 million new cancer cases every year by 2020. Source : http://www.transparencymarketresearch.com/peptide-therapeutics-market.html

1. Transparency Market Research
Peptide Therapeutics Buy Now
Market - Global Industry
Request Sample
Analysis, Size, Share,
Growth, Trends And Published Date: Mar 2013
Forecast, 2012 – 2018
Single User License: US $ 4595
128 Pages Report
Multi User License: US $ 7595
Corporate User License: US $ 10595
REPORT DESCRIPTION
Peptide Therapeutics Market - Global Industry Analysis, Size, Share, Growth,
Trends And Forecast, 2012 – 2018
The Peptide therapeutics is currently offering a new commercial potential to pharmaceuticals
and biotechnology industry. To exploit this emerging market, large pharmaceutical and
biotechnological firms are actively investing in development of newer peptides for various
applications and are also opting for newer technologies for syntheses of these peptides.
Cancer is the leading cause of death globally; according to the WHO (World Health
Organization), around 12.7 million new cancer cases occurred in the year 2008. About 7
million people die from cancer every year and it is estimated that there will be more than 16
million new cancer cases every year by 2020. With rise in cancer patients and metabolic
diseases like diabetes, there has been a push in growth for peptide molecules since
chemotherapy, which is the major mode of treatment for cancer, is facing major challenges
due to its inability to deliver the correct amount of drug directly. In addition, it affects the
normal cells in the body.

2. Browse Report : Peptide Therapeutics Market
Likewise, peptide application in various other treatments has opened a promising avenue for
future growth of this market. New routes of peptide administration are being investigated;
however the parenteral route continues to dominate this market and accounted for a share
of almost 86% of the entire market. Similarly, the technology market is ruled by LPPS (long
phase peptide syntheses) and is anticipated to decline owing to huge demand for solid
phase peptide syntheses and hybrid syntheses.
This report analyzes the peptide therapeutics market by types of applications (cancer,
metabolic, neurological diseases and others), route of administration, by types (innovative
and generic), by API therapeutics market (in-house vs. CMO), by peptide therapeutics, and
technology. Each of these markets is analyzed by studying the current and future market
scenario, with estimation for the period 2010 – 2018 in terms of value in USD million.
The peptide therapeutics market is also segmented based on geography into North America,
Europe, Asia and rest of the world (RoW) regions. The market for all these geographical
regions is provided in the report in terms of revenue. The report provides complete analysis
of the factors responsible for driving and restraining the global peptide therapeutics
market.
Competitive landscape is provided with market players profiled with attributes like company
overview, financial overview, business strategies, product portfolio and recent
developments. Market shares in 2011 for the key players and CMO players are provided and
recommendations to accentuate market shares and ensure sustainability are provided in
this report
Key market players profiled in this report are Eli Lilly, Roche, Amylin, Novo-Nordisk, Ipsen
and others. While CMOs major players profiled are Bachem, Lonza, Peptisyntha, Polypeptide
group and others.
Peptide Therapeutics Market, by Applications
 Cancer
 Metabolic
 Cardiovascular
 Dermatology
 Anti-Infection
 Neurology
 Gastro Intestinal
 Renal

3.  Respiratory
 Pain
 Others
Peptide Therapeutics Market, by Route of Administration
 Parenteral
 Oral
 Pulmonary
 Mucosal
 Others
Peptide Therapeutics Market, by Types
 Innovative
 Generics
Peptide Therapeutics Market, by API Peptide
 In-House
 CMO (Contract Manufacturing Organization)
Peptide Therapeutics by Technology
 Liquid Phase Peptide Synthesis (LPPS)
 Solid Phase Peptide Synthesis (SPPS)
 Hybrid
Peptide Therapeutics Market, by Geography
 North America
 Europe
 Asia
 RoW
Browse Report : http://www.transparencymarketresearch.com/peptide-
therapeutics-market.html

4. TABLE OF CONTENTS
Chapter 1 Preface
1.1 Report description
1.2 Market segmentation
1.3 Scope of the report
1.4 Research methodology
1.5 Assumptions
Chapter 2 Executive Summary
2.1.1 Global peptide therapeutics market revenues, 2010 – 2018 (USD Million)
2.1.2 Global peptide therapeutics market revenues, by region, 2010 - 2018 (USD Million)
2.1.3 Global API peptide therapeutics market, 2011 (USD Million)
2.1.4 Global peptide therapeutics market, by route of administration, 2011 & 2018 (%)
Chapter 3 Global Peptide Therapeutics Market Dynamics
3.1 Overview
3.2 Drivers
3.2.1 Increase in cancer patient population to propel the growth of new peptides
3.2.2 Rise in metabolic disorders to escalate the growth of peptides market
3.2.3 Rise in R&D pipeline of peptide drugs is expected to bring considerable growth in
coming years
3.2.3.1 Global peptide therapeutics trials growth, 1970 - 2011
3.2.4 Technological enhancement has boosted the growth of the market with radical
reduction in total production cost of peptides
3.3 Restraints & challenges
3.3.1 Increasing complexity of peptides is a huge challenge for manufacturers
3.3.2 Lack of regulatory standards hampering the growth of the market

5. 3.3.3 Matching equipments with customer requirements is a major challenge for API peptide
manufacturers
3.4 Opportunities
3.4.1 Rise in cancer vaccine to drive the future market
3.4.2 Generic peptides market to flourish with patent cliff expected in the forecast period
3.4.3 Small biotech firms collaborating with large pharmaceutical companies to explore
further growth
3.4.3.1 Global scenario of acquisitions of biotech firms by large pharma giants
3.4.3.2 Major peptide drugs and sales, 2011 (USD Million)
3.5 Porters five forces analysis
3.5.1 Porter’s five forces analysis of global peptide therapeutics market
3.5.2 Bargaining power of suppliers
3.5.3 Bargaining power of buyers
3.5.4 Threat of new entrants
3.5.5 Threat of substitutes
3.5.6 Competitive rivalry
3.6 Market attractiveness analysis
3.6.1 Market attractiveness analysis of the peptide therapeutics market by geography
3.7 Peptide therapeutics - emerging technologies & trends
3.8 Regulatory policies
Chapter 4 Global Peptide Therapeutics Market Analysis, By Applications
4.1.1 Introduction
4.1.1.1 Global peptide therapeutics market revenue, by applications 2012-2018 (USD
Million)
4.1.2 Cancer
4.1.2.1 Global cancer peptide therapeutics pipeline drugs analysis, number of trials, 2009 -
2012
4.1.2.2 Global cancer peptide therapeutics market revenues, 2010 – 2018 (USD Million)

6. Browse Report : http://www.transparencymarketresearch.com/peptide-
therapeutics-market.html
4.1.3 Metabolic
4.1.3.1 Global metabolic peptide therapeutics pipeline drugs analysis, number of trials,
2009 - 2012
4.1.3.2 Global metabolic peptide therapeutics market revenues, 2010 – 2018 (USD Million)
4.1.4 Cardiovascular
4.1.4.1 Global cardiovascular peptide therapeutics pipeline drugs analysis, number of trials,
2009 - 2012
4.1.4.2 Global cardiovascular peptide therapeutics market revenues, 2010 – 2018 (USD
Million)
4.1.5 Dermatology
4.1.5.1 Global dermatology pipeline drugs analysis, number of trials, 2009 - 2012
4.1.5.2 Global dermatology peptides market revenues, 2010 – 2018 (USD Million)
4.1.6 Anti-Infection
4.1.6.1 Global anti-infection drugs analysis, number of trials, 2009 - 2012
4.1.6.2 Global anti-infection peptides market revenues, 2010 – 2018 (USD Million)
4.1.7 Neurology
4.1.7.1 Global neurology pipeline drugs analysis, number of trials, 2009 - 2012
4.1.7.2 Global neurology peptides market revenues, 2010 – 2018 (USD Million)
4.1.8 Gastro Intestinal
4.1.8.1 Global gastro intestinal pipeline drugs analysis, number of trials, 2009 - 2012
4.1.8.2 Global gastro intestinal peptides market revenues, 2010 - 2018 (USD Million)
4.1.9 Renal
4.1.9.1 Global renal pipeline drugs analysis, number of trials, 2009 - 2012
4.1.9.2 Global renal peptides market revenues, 2010 – 2018 (USD Million)
4.1.10 Respiratory
4.1.10.1 Global respiratory pipeline drugs analysis, number of trials, 2009 - 2012

7. 4.1.10.2 Global respiratory peptides market revenues, 2010 – 2018 (USD Million)
4.1.11 Pain
4.1.11.1 Global pain pipeline drugs analysis, number of trials, 2009 - 2012
4.1.11.2 Global pain peptides market revenues, 2010 - 2018 (USD Million)
4.1.12 Others
4.1.12.1 Global other pipeline drugs analysis, number of trials, 2009 - 2012
4.1.12.2 Global other peptides market revenues, 2010 – 2018 (USD Million)
Chapter 5 Global Peptide Therapeutics Market, by Route of Administration
5.1 Introduction
5.1.1 Global peptide therapeutics market revenues, by route of administration, 2010 - 2018
(USD Million)
5.1.2 Methods of delivery for peptide drugs
5.2 Parenteral Route
5.2.1 Global peptide therapeutics market revenues, by parenteral route of administration,
2010 - 2018 (USD Million)
5.3 Oral Route
5.3.1 Global peptide therapeutics market revenues, by oral route of administration, 2010 -
2018 (USD Million)
5.4 Pulmonary Route
5.4.1 Global peptide therapeutics market revenues, by pulmonary route of administration,
2010 - 2018 (USD Million)
5.5 Mucosal Route
5.5.1 Global peptide therapeutics market revenues, by mucosal route of administration,
2010 - 2018 (USD Million)
5.6 Others (Intradermal & Nasal)
5.6.1 Global peptide therapeutics market revenues, by other routes of administration, 2010
- 2018 (USD Million)
Browse Report : http://www.transparencymarketresearch.com/peptide-
therapeutics-market.html

8. Chapter 6 Peptide Therapeutics Market – Generic & Innovative Segments
6.1 Introduction
6.1.1 Global peptide therapeutics market, by types revenues, 2010 - 2018 (USD million)
6.2 Peptide Therapeutics – Innovative market
6.2.1 Global innovative peptide therapeutics market revenues, 2010 - 2018 (USD Million)
6.3 Peptide Therapeutics – Generic market
6.3.1 Global generic peptide therapeutics market revenues, 2010 - 2018 (USD Million)
Chapter 7 API Peptide Therapeutics Market, In-house Vs CMO
7.1 Introduction
7.2 API peptide therapeutics – In-house market
7.2.1 Global API peptide therapeutics in-house market revenues, 2010-2018 (USD Million)
7.3 Contract Manufacturing Organizations (CMO)
7.3.1 Global API peptide therapeutics CMOs market revenues, 2010 - 2018 (USD Million)
Chapter 8 Peptide Therapeutics Market, By Technology
8.1 Introduction
8.1.1 Global peptide therapeutics market revenues, by technology, 2010 – 2018 (USD
Million)
8.2 Solid Phase Peptide Synthesis (SPPS)
8.2.1 Global peptide therapeutics SPPS technology market revenues, 2010 - 2018 (USD
Million)
8.3 Liquid Phase Peptide Synthesis (LPPS)
8.3.1 Global peptide therapeutics LPPS technology market revenues, 2010 - 2018 (USD
Million)
8.4 Hybrid Technology
8.4.1 Global peptide therapeutics hybrid technology market revenues, 2010 - 2018 (USD
Million)

9. Chapter 9 Peptide Therapeutics Market, By Geography
9.1 Introduction
9.1.1 Global peptide therapeutics market share, by geography, 2011 - 2018
9.2 North America
9.2.1 North America peptide therapeutics market revenues, 2010 – 2018 (USD Million)
9.3 Europe
9.3.1 Europe peptide therapeutics market revenues, 2010 – 2018 (USD Million)
9.4 Asia
9.4.1 Asia peptide therapeutics market revenues, 2010 - 2018 (USD Million)
9.5 Rest of World
9.5.1 RoW peptide therapeutics market revenues, 2010 - 2018 (USD Million)
Chapter 10 Market Share Analysis
10.1 Market share by key players
10.2 Market share by key players in peptide drugs market
10.2.1 Global peptide therapeutics market share analysis of key players, 2011 (%)
10.3 Market share by key players in CMO segment
10.3.1 Global peptide therapeutics: market share analysis of key CMO players, 2011 (%)
Chapter 11 Recommendations
11.1 Success strategies
11.1.1 Rigorous research and development (R&D) initiatives
11.1.2 Investing in emerging economies
11.1.3 Investing in recent technologies such as HPPS TEchnology
11.1.4 Mergers and acquisitions
11.2 Barriers to be considered
11.2.1 The high cost of peptide synthesis

10. 11.2.2 Weak pipeline peptide drug candidates in phase III
Chapter 12 Company Profiles
12.1 Bachem Holding AG
12.1.1 Company overview
12.1.2 Financial overview
12.1.3 Strategic overview
12.1.3.1 Collaborations
12.1.3.2 Expansion
12.1.3.3 Divestiture
12.1.3.4 Recent developments
12.2 Eli Lilly and Company
12.2.1 Company overview
12.2.2 Financial overview
12.2.3 Strategic overview
12.2.3.1 Agreements
12.2.3.2 Approvals
12.2.4 Recent developments
12.3 Pfizer, Inc.
12.3.1 Company overview
12.3.2 Financial overview
12.3.3 Strategic overview
12.3.3.1 Mergers and acquisitions
12.3.3.2 Divestiture
12.3.3.3 Approvals
12.3.4 Recent developments
12.4 Amgen, Inc.

11. 12.4.1 Company overview
12.4.2 Financial overview
12.4.3 Strategic overview
12.4.3.1 Mergers and acquisitions
12.4.3.2 Licensing
12.4.4 Recent developments
12.5 Takeda Pharmaceutical Company Limited
12.5.1 Company overview
12.5.2 Financial overview
12.5.3 Strategic overview
12.5.3.1 Partnerships and collaborations
12.5.3.2 Mergers and acquisitions
12.5.4 Recent developments
12.6 Teva Pharmaceuticals
12.6.1 Company overview
12.6.2 Financial overview
12.6.3 Strategic overview
12.6.3.1 Mergers and acquisitions
12.6.3.2 Investing in generic and biosimilar segments
12.6.4 Recent developments
12.7 Lonza Inc.
12.7.1 Company overview
12.7.2 Financial overview
12.7.3 Strategic overview
12.7.3.1 Investing in emerging economies
12.7.3.2 Mergers and acquisitions
12.7.4 Recent developments

12. 12.8 Peptisyntha
12.8.1 Company overview
12.8.2 Financial overview
12.8.3 Strategic overview
12.8.3.1 Arranging and participating in trade shows
12.8.3.2 Continuous manufacturing expansion
12.9 Sanofi
12.9.1 Company overview
12.9.2 Financial overview
12.9.3 Strategic overview
12.9.3.1 Acquisitions
12.9.3.2 Divestments
12.9.4 Recent developments
12.10 Ipsen
12.10.1 Company overview
12.10.2 Financial overview
12.10.3 Strategic overview
12.10.3.1 Large investment in research and development
12.10.3.2 Global expansion through partnership
12.10.4 Recent developments
12.11 PolyPeptide Group.
12.11.1 Company overview
12.11.2 Strategic overview
12.11.2.1 Focus on product portfolio extension and quality product development
12.11.2.2 Global expansion through merger and acquisition
12.12 Amylin Pharmaceuticals LLC - Bristol-Myers Squibb (BMS)
12.12.1 Company overview

13. Browse Report : http://www.transparencymarketresearch.com/peptide-
therapeutics-market.html
12.12.2 Amylin Pharmaceuticals LLC
12.12.3 Financial overview
12.12.4 Strategic overview (Amylin Pharmaceuticals LLC)
12.12.4.1 Entering into strategic collaborations
12.12.4.2 Corporate social responsibility
12.12.4.3 Rigorous R&D initiatives
12.12.5 Recent developments
12.13 AstraZeneca PLC
12.13.1 Company overview
12.13.2 Financial overview
12.13.3 Strategic overview
12.13.3.1 Rigorous R&D initiatives
12.13.3.2 Investing in emerging economies
12.13.4 Recent developments
12.14 Roche
12.14.1 Company overview
12.14.2 Financial overview
12.14.3 Strategic overview
12.14.3.1 Research and development initiatives
12.14.3.2 Focus on personalized healthcare
12.14.3.3 Focus on new and emerging markets
12.14.3.4 Funding awareness programs
12.14.4 Recent developments
12.15 GlaxoSmithKline (GSK)

14. 12.15.1 Company overview
12.15.2 Financial overview
12.15.3 Strategic overview
12.15.3.1 Research and development initiatives
12.15.3.2 Direct to Consumer Advertising
12.15.3.3 Mergers and acquisitions
12.15.4 Recent developments
12.16 Merck & Co.
12.16.1 Company overview
12.16.2 Financial overview
12.16.3 Strategic overview
12.16.3.1 Corporate social responsibility
12.16.3.2 R&D Initiatives
12.16.3.3 Strategic alliances and out-licensing
12.16.4 Recent developments
12.17 Novartis AG
12.17.1 Company overview
12.17.2 Financial overview
12.17.3 Strategic overview
12.17.3.1 Mergers and acquisitions
12.17.3.2 Memorandum of understanding
12.17.4 Recent developments
12.18 Novo-Nordisk A/S
12.18.1 Company overview
12.18.2 Financial overview
12.18.3 Strategic overview
12.18.3.1 Partnerships and alliances

15. 12.18.4 Agreements
12.18.5 Recent developments
About Us:
Transparency Market Research is a market intelligence company providing global business
information reports and services. Our exclusive blend of quantitative forecasting and trends
analysis provides forward-looking insight for thousands of decision makers.
We are privileged with highly experienced team of Analysts, Researchers and Consultants,
who use proprietary data sources and various tools and techniques to gather, and analyze
information. Our business offerings represent the latest and the most reliable information
indispensable for businesses to sustain a competitive edge.
Contact:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/